Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Kite, A Gilead Company.

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond

ASCO: Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond


Friday, June 1, 2018
Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
Salon A 1 & 2, Lower Level
720 South Michigan Avenue
Chicago, IL 60605

What you'll learn:

  • How to select eligible patients for CAR T-cell therapy
  • Clinical data that is changing treatment paradigms
  • Addressing cytokine-release syndrome and other toxicities

Overview:

The recent approval of chimeric antigen receptor (CAR) T cells has given even patients with highly chemorefractory hematologic malignancies additional treatment options. While these new therapies hold the promise of benefit for an expanding number of patients, becoming familiar with new therapeutic modalities can be very challenging for busy clinicians. We would like to help you to develop familiarity and competency with CAR T cells, which may offer the chance to improve outcomes for your patients. CAR T cells differ from traditional systemic therapies with respect to patient selection, manufacture, and treatment administration. To that end, we have developed an exciting educational opportunity for you to further enhance your skills on the frontlines of cancer care.

This symposium will provide you with the opportunity to learn from an expert panel of physicians in a dynamic setting. We have created a format that features both didactic and interactive panel discussions to help illustrate the application of clinical data in real-world patient care scenarios.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Kite, A Gilead Company.

Target Audience

This educational program is directed toward medical oncologists, hematologists, nurses, and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy for patients with lymphoid malignancies. Fellows, researchers, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with lymphoid malignancies are also invited to attend.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Recognize the unique mechanistic characteristics of CAR T-cell therapy for management of hematologic malignancies and the role of CAR T-cell therapy in the context of other emerging treatments
  • Understand the nuances of the manufacture of CAR T-cell therapy, including the quality standards of manufacturing, as well as the clinical relevance of production techniques and standards
  • Evaluate clinical trial data in the context of CAR T-cell therapy in the evolving treatment paradigms of hematologic malignancies
  • Define the potential treatment-related toxicities of CAR T-cell therapy and best practices for adverse event monitoring, management, and mitigation

Program Chair

Andre H. Goy, MD, MS
Chairman and Executive Director
Lymphoma Division Chief - John Theurer Cancer Center
Chief Science Officer – RCCA
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Hackensack, NJ

Click to see all our ASCO programs!







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By